Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Quadrivalent Influenza Virus Vaccine, High-dose quadrivalent influenza virus vaccine (QIV HD1)
High-dose quadrivalent influenza virus vaccine · 1 trial · 1 indication
Solicited injection site: Pain, Redness, Swelling, Induration, and Ecchymosis. Solicited systemic reaction: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Unsolicited adverse events, including serious adverse events, will also be collected
| Arm | Type | Description |
|---|---|---|
| QIV HD1 Group | EXPERIMENTAL | Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1) |
| QIV HD2 Group | EXPERIMENTAL | Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2) |
| TIV HD1 Group | ACTIVE_COMPARATOR | Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine |
| TIV HD2 Group | ACTIVE_COMPARATOR | Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine |
| Name | Type | Description |
|---|---|---|
| High-dose quadrivalent influenza virus vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (IM), injected into the deltoid area |
| High-dose influenza virus vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (IM), injected into the deltoid area |
| High-dose trivalent inactivated influenza vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (IM), injected into the deltoid area |
Inclusion Criteria: * Aged ≥ 65 years on the day of inclusion * Informed consent form has been signed and dated * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Participation at the time of trial enrollment (or in the 4 weeks preceding the trial...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
The high-dose quadrivalent influenza virus vaccine is an investigational vaccine developed by Sanofi for the prevention of influenza. It is designed to provide protection against four influenza virus strains and is being studied in adults aged 65 years and older. It is also known as the Quadrivalent Influenza Virus Vaccine.
The high-dose quadrivalent influenza virus vaccine is intended for the prevention of influenza in adults aged 65 years and older. It targets four influenza virus strains. The vaccine is investigational and has been studied in a Phase 2 clinical trial.
The high-dose quadrivalent influenza virus vaccine is developed by Sanofi, which trades on the New York Stock Exchange under the ticker symbol SNY. Sanofi is a global pharmaceutical company with a portfolio that includes vaccines.
The high-dose quadrivalent influenza virus vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 2 trial has been completed.
The high-dose quadrivalent influenza virus vaccine has been studied in one clinical trial, NCT02553343, titled "A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older." This Phase 2 trial was completed and enrolled 792 participants in the United States.
Yes, the high-dose quadrivalent influenza virus vaccine is also known as the Quadrivalent Influenza Virus Vaccine. Both names refer to the same Sanofi investigational vaccine for influenza.